The following items are requested, if applicable, when submitting an abstract:
- Trial Registration
- Ethics Approval
- Authors and Institutions
- Tables, Figures and Images
In addition to the items above, Young Investigator Award Abstracts need to include the following:
- A letter of recommendation from a supervisor (.doc, .docx, .pdf)
- Confirm they are a SITC member
- Confirm they are a student, postdoctoral research fellow, clinical fellow, or junior faculty with three or fewer years on staff, and if so, identify which category they represent
- Indicate the percentage of contribution by the primary and presenting author in regards to conception and design, collection and assembly, data analysis and interpretation, and abstract writing
Clinical Trial In Progress and Clinical Trial Complete abstracts need to include the following:
Abstract submitters must answer whether the abstract being submitted is based on a clinical trial and will be presenting clinical data. If the abstract being submitted is a clinical trial abstract, please mark whether it is an in progress or a completed clinical trial. For more information about what is considered a clinical trial in progress, click here. If the abstract will incorporate basic or pre-clinical research, please mark that it is not a clinical trial abstract. Please note, the response to this question will determine which abstract categories you see.
Inclusion Enrollment Report Data Table: To assist with SITC’s commitment to improve diversity and inclusion in clinical trials, it is asked that clinical trial abstract submitters please complete the Inclusion Enrollment Report data table, which follows the NIH data template. This data will not be shared with abstract reviewers and will not be included in the publication of accepted abstracts. The data will only be accessible to SITC staff and will only be reported in aggregate. Presenters for abstracts that are accepted for a poster or oral presentation are encouraged to include this data in the presentation if applicable. Thank you for helping SITC monitor the landscape of diversity in clinical trial enrollment.
Late-breaking Abstracts need to include the following:
- Clinical Study
- Closure date of the study
- Primary clinical endpoint for analysis
- Type of analysis
- Lab-based Study
- Provide an explanation why the experiment(s) could not be completed before the Regular Abstract submission deadline, June 27, 2023, and needs to be considered for late-breaking submission.